Form 4: uniQure Executive Walid Abi-Saab Reports Share Transactions

Walid Abi-Saab, Chief Medical Officer of uniQure N.V., reports acquisition of restricted share units and stock options, as well as sales of ordinary shares to cover withholding taxes.

Summary

• On March 3, 2025, Walid Abi-Saab, Chief Medical Officer of uniQure N.V., was granted 38,000 restricted share units and 66,000 stock options.
• On March 4, 2025, Abi-Saab sold 1,350 ordinary shares at a weighted average price of $10.29 per share to cover estimated withholding taxes upon vesting of restricted share units.
• Following these transactions, Abi-Saab directly owns 151,903 ordinary shares and 66,000 stock options.
• The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to continued relationship with the Issuer.
• The stock options vest 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to continued relationship with the Issuer.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine transactions related to equity compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The grant of restricted share units and stock options aligns Abi-Saab's interests with those of the shareholders.
• The vesting schedules for the restricted share units and stock options incentivize continued service with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests. These filings are common in the biotechnology industry, where equity-based compensation is frequently used.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotech industry to attract and retain talent.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize stock options and restricted stock units as part of their compensation packages.
• The vesting schedules described are fairly standard, with annual or quarterly vesting periods tied to continued employment.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• Shareholders can monitor insider transactions to assess management's alignment with their interests.

Key Dates